Bafna Pharmaceuticals Limited

NSE:BAFNAPH.NS

81.76 (INR) • At close November 4, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12012 Q42012 Q32012 Q22012 Q1
Revenue 332.863413.981284.422406.782419.471422.438342.184219.608169.268149.825204.601284.392212.586218.405174.753151.996167.025131.329109.252115.65168.493225.698130.74988.379104.232592.963259.909521.185341.154
Cost of Revenue 316.768348.859232.917287.935265.83278.422245.134137.879104.50696.481123.791161.792130.794126.439111.84599.236117.03646.84671.31888.64663.427178.80289.10756.51783.465457.439156.812475.6235.86
Gross Profit 16.09565.12251.505118.847153.641144.01697.0581.72964.76253.34480.81122.681.79291.96662.90852.7649.98984.48337.93427.0055.06646.89641.64231.86220.767135.524103.09745.585105.294
Gross Profit Ratio 0.0480.1570.1810.2920.3660.3410.2840.3720.3830.3560.3950.4310.3850.4210.360.3470.2990.6430.3470.2340.0740.2080.3180.3610.1990.2290.3970.0870.309
Reseach & Development Expenses 0000015.21200014.72800013.58900010.0950007.5270000000
General & Administrative Expenses 0000018.42500040.46900010.16100033.31800050.990000000
Selling & Marketing Expenses 000003.6640000.9630000.5630000.6190000.5620000000
SG&A 18.42448.95926.96430.3242.73522.08922.36918.95835.01941.43236.34638.98814.35410.72432.53730.15117.93633.93724.19424.34823.14951.55222.19921.79220.6120000
Other Expenses -3.455.1539.7911.5918.691-0.83614.1276.42213.0144.2724.8731.7641.7-4.3440.3912.2711.755-9.1840.3295.9133.0173.5083.101-0.3470134.39257.771-20.85257.698
Operating Expenses 21.87448.95984.96391.219102.81579.63775.52167.55861.0368.23464.54479.85761.56261.7451.00550.03333.46546.46645.73937.98243.91184.29438.94237.55437.421134.39257.771-20.85257.698
Operating Income -5.77916.163-23.66729.21850.82663.54335.65620.5933.732-12.82916.26542.74320.2330.22611.9034.99916.52438.017-7.805-10.977-38.845-37.3982.7-5.692-16.6541.13245.32666.43747.596
Operating Income Ratio -0.0170.039-0.0830.0720.1210.150.1040.0940.022-0.0860.0790.150.0950.1380.0680.0330.0990.289-0.071-0.095-0.567-0.1660.021-0.064-0.160.0020.1740.1270.14
Total Other Income Expenses Net -1.457-1.609-5.757-4.37912.685-7.041-5.707-4.5049.8893.3310.763-18.980.64-3.866-2.899-0.2121.592202.088-215.8385.4681.749-97.748-1.533-6.54-7.257-10.401-27.778-25.524-26.298
Income Before Tax -7.23614.554-29.42424.83963.51156.50229.94916.08913.62111.41517.02823.76320.8726.369.0044.78718.116240.105-223.643-5.509-37.096-135.1461.167-12.232-23.911-9.26917.54840.91321.298
Income Before Tax Ratio -0.0220.035-0.1030.0610.1510.1340.0880.0730.080.0760.0830.0840.0980.1210.0520.0310.1081.828-2.047-0.048-0.542-0.5990.009-0.138-0.229-0.0160.0680.0780.062
Income Tax Expense 012.66712.74812.28918.6912.783-0.00311.15813.01423.8764.8731.7641.701-6.6460.3901.75615.778-0.3525.913-15.82210.560.533-0.3480.057-4.023.4634.6610.686
Net Income -7.23614.554-29.42424.83963.51153.71929.95216.08913.621-10.1517.02823.76320.8726.369.0044.78718.116-4.133-223.291-5.509-21.275-140.8080.634-12.232-23.968-5.75414.08536.25310.612
Net Income Ratio -0.0220.035-0.1030.0610.1510.1270.0880.0730.08-0.0680.0830.0840.0980.1210.0520.0310.108-0.031-2.044-0.048-0.311-0.6240.005-0.138-0.23-0.010.0540.070.031
EPS -0.310.62-1.241.052.682.271.270.680.58-0.450.720.950.881.110.380.27.66-1.75-9.44-0.25-0.9-59.540.04-0.52-10.1-2.430.751.110.58
EPS Diluted -0.310.62-1.241.052.682.271.270.680.58-0.450.720.950.881.110.380.27.66-1.75-9.44-0.25-0.9-59.540.04-0.52-10.1-2.430.751.110.58
EBITDA 8.6628.874-10.95941.62981.64278.79549.6431.83729.6124.40833.22158.73536.5438.56722.47815.13527.75435.064219.3852.163-25.65-17.0814.8241.484-7.05129.74165.5782.42465.253
EBITDA Ratio 0.0260.07-0.0390.1020.1950.1870.1450.1450.1750.1630.1620.2070.1720.1770.1290.10.1660.2672.0080.019-0.374-0.0760.1130.017-0.0680.050.2520.1580.191